Holen Sie sich die Stockscreener-App
4.74
0.85%
0.04
Handel nachbörslich:
4.74
Schlusskurs vom Vortag:
$4.70
Offen:
$4.61
24-Stunden-Volumen:
264.41K
Relative Volume:
1.19
Marktkapitalisierung:
$98.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.17M
KGV:
-3.5639
EPS:
-1.33
Netto-Cashflow:
$-91.71M
1W Leistung:
-11.73%
1M Leistung:
-23.18%
6M Leistung:
-27.74%
1J Leistung:
-40.01%
1-Tages-Spanne:
$4.61
$4.8897
1-Wochen-Bereich:
$4.61
$5.48
52-Wochen-Spanne:
$4.61
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Firmenname
Adverum Biotechnologies Inc
Sektor
Branche
Telefon
(650) 649-1004
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Vergleichen Sie ADVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.74 | 98.60M | 0 | -117.17M | -91.71M | -11.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Hochstufung | Truist | Hold → Buy |
| 2021-07-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Herabstufung | Truist | Buy → Hold |
| 2020-12-16 | Eingeleitet | UBS | Neutral |
| 2020-11-12 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-05 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-09-13 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-06-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-11-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Herabstufung | SunTrust | Buy → Hold |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Eingeleitet | SunTrust | Buy |
| 2018-02-15 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten
StockNews.com Downgrades Adverum Biotechnologies (NASDAQ:ADVM) to Sell - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.com - Defense World
Where are the Opportunities in (ADVM) - Stock Traders Daily
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Fmr LLC - MarketBeat
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 11.1% in November - MarketBeat
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1% - Defense World
ADVM stock touches 52-week low at $5.61 amid market challenges - Investing.com
StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold - Defense World
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Awards Key Talent Inducement Grants, Strengthens Team with Strategic Equity Package - StockTitan
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director - Business Wire
Adverum Biotechnologies (NASDAQ:ADVM) Receives Buy Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum Biotechnologies, Inc. Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Adverum to present gene therapy data for eye disease - Investing.com India
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - The Manila Times
Adverum to present gene therapy data for eye disease By Investing.com - Investing.com UK
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
FMR LLC Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is BML Capital Management LLC's 6th Largest Position - MarketBeat
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles By Investing.com - Investing.com Nigeria
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles - Investing.com India
FY2024 Earnings Forecast for ADVM Issued By Chardan Capital - MarketBeat
HC Wainwright Issues Pessimistic Forecast for ADVM Earnings - Defense World
Morgan Stanley's Strategic Reduction in Adverum Biotechnologies Inc Shares - GuruFocus.com
(ADVM) Trading Advice - Stock Traders Daily
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Posts Earnings Results - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Thomas Chalberg - World Economic Forum
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
When (ADVM) Moves Investors should Listen - Stock Traders Daily
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adverum Biotechnologies Inc-Aktie (ADVM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
9.11 |
80,718 |
735,736 |
2,182,264 |
| Scopa James Paul | Director |
Feb 07 '24 |
Buy |
1.35 |
100,000 |
135,000 |
100,000 |
| Lupher, Jr. Mark L. | Director |
Feb 07 '24 |
Buy |
1.35 |
130,000 |
175,500 |
130,000 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):